From Noncoding Variant to Phenotype via SORT1 at the 1p13 Cholesterol Locus

DSpace/Manakin Repository

From Noncoding Variant to Phenotype via SORT1 at the 1p13 Cholesterol Locus

Citable link to this page

 

 
Title: From Noncoding Variant to Phenotype via SORT1 at the 1p13 Cholesterol Locus
Author: Musunuru, Kiran; Strong, Alanna; Frank-Kamenetsky, Maria; Lee, Noemi E.; Ahfeldt, Tim; Sachs, Katherine V.; Li, Xiaoyu; Li, Hui; Kuperwasser, Nicolas; Ruda, Vera M.; Pirruccello, James Paul; Muchmore, Brian; Prokunina-Olsson, Ludmila; Hall, Jennifer L.; Schadt, Eric E.; Morales, Carlos R.; Lund-Katz, Sissel; Phillips, Michael C.; Wong, Jamie; Cantley, William; Racie, Timothy; Ejebe, Kenechi G.; Orho-Melander, Marju; Melander, Olle; Koteliansky, Victor; Fitzgerald, Kevin; Krauss, Ronald M.; Cowan, Chad A.; Kathiresan, Sekar; Rader, Daniel J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Musunuru, Kiran, Alanna Strong, Maria Frank-Kamenetsky, Noemi E. Lee, Tim Ahfeldt, Katherine V. Sachs, Xiaoyu Li, et al. 2010. “From Noncoding Variant to Phenotype via SORT1 at the 1p13 Cholesterol Locus.” Nature 466 (7307) (August): 714–719. doi:10.1038/nature09266.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: Recent genome-wide association studies (GWASs) have identified a locus on chromosome 1p13 strongly associated with both plasma low-density lipoprotein cholesterol (LDL-C) and myocardial infarction (MI) in humans. Here we show through a series of studies in human cohorts and human-derived hepatocytes that a common noncoding polymorphism at the 1p13 locus, rs12740374, creates a C/EBP (CCAAT/enhancer binding protein) transcription factor binding site and alters the hepatic expression of the SORT1 gene. With small interfering RNA (siRNA) knockdown and viral overexpression in mouse liver, we demonstrate that Sort1 alters plasma LDL-C and very low-density lipoprotein (VLDL) particle levels by modulating hepatic VLDL secretion. Thus, we provide functional evidence for a novel regulatory pathway for lipoprotein metabolism and suggest that modulation of this pathway may alter risk for MI in humans. We also demonstrate that common noncoding DNA variants identified by GWASs can directly contribute to clinical phenotypes.
Published Version: doi:10.1038/nature09266
Other Sources: http://www.ncbi.nlm.nih.gov/pubmed/20686566
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34903179
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters